analyst
TV
NASDAQ · TVTX
Travere Therapeutics, Inc.
Healthcare · Biotechnology
$65.67
Down-$1.85 (-2.74%)
Updated Aug 31, 2026, 4:21 AM
SID Score
6.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.13B
- P/E ratio
- -35.27
- Dividend yield
- 0.00%
- 52-week range
- $17.27 – $67.85
- Volume
- 808.52K
- Avg. volume
- 1.89M
Price performance
TVTX price history
1M range · 20 trading sessions · Daily adjusted prices
TVTX closed at $65.67 after 20 trading sessions, up 19.44% for the selected period.
- Last close
- $65.67
- Period change
- +19.44%
- Period low
- $54.98
- Period high
- $67.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $67.27 | $67.45 | $65.37 | $65.67 | 808.52K |
| Aug 27, 2026 | $66.69 | $67.85 | $65.65 | $67.52 | 911.64K |
| Aug 26, 2026 | $66.91 | $67.50 | $65.22 | $67.12 | 1.22M |
| Aug 25, 2026 | $65.74 | $67.34 | $65.74 | $67.01 | 1.51M |
| Aug 24, 2026 | $65.78 | $65.795 | $63.71 | $65.22 | 1.04M |
| Aug 21, 2026 | $64.78 | $66.38 | $64.495 | $65.71 | 1.62M |
| Aug 20, 2026 | $64.82 | $65.54 | $64.015 | $64.46 | 1.07M |
| Aug 19, 2026 | $65.00 | $66.19 | $63.34 | $65.96 | 1.52M |
| Aug 18, 2026 | $62.87 | $64.00 | $62.50 | $63.90 | 884.91K |
| Aug 17, 2026 | $62.15 | $64.38 | $61.619 | $63.53 | 1.57M |
| Aug 14, 2026 | $60.76 | $62.48 | $60.47 | $62.14 | 1.19M |
| Aug 13, 2026 | $63.328 | $63.328 | $61.055 | $61.43 | 1.29M |
| Aug 12, 2026 | $61.34 | $62.32 | $60.40 | $62.16 | 1.04M |
| Aug 11, 2026 | $60.75 | $61.9656 | $60.20 | $60.21 | 1.28M |
| Aug 10, 2026 | $60.56 | $62.57 | $60.56 | $60.89 | 1.76M |
| Aug 7, 2026 | $63.53 | $63.71 | $60.67 | $61.32 | 1.23M |
| Aug 6, 2026 | $63.69 | $65.45 | $62.10 | $62.45 | 2.87M |
| Aug 5, 2026 | $62.00 | $66.24 | $61.00 | $62.76 | 6.31M |
| Aug 4, 2026 | $54.93 | $56.67 | $54.22 | $56.02 | 2.46M |
| Aug 3, 2026 | $54.82 | $56.00 | $53.42 | $54.98 | 1.91M |
Latest TVTX news
The latest Smart Investors Daily articles mentioning TVTX.
Stock researchResearch & News · SEC Filings
Loading stock research…